The Medicines Company Stops Phase 2b Trial of MDCO-2010
The Medicines Company (NASDAQ: MDCO) today announced that it has voluntarily discontinued its Phase 2b dose-ranging study of MDCO-2010, a serine protease inhibitor which was being developed to reduce blood loss during surgery. This action was taken in response to serious unexpected patient safety issues encountered during the trial, which had so far recruited 44 of a planned 90 patients in the first stage of the study.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.